Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers

NCT01859117 is registered in ClinicalTrials.gov with Celularity Incorporated as lead sponsor.

NCT NCT01859117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01859117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers
Lead sponsor
Celularity Incorporated
Phase
Phase 1
Overall status
Completed
Start date
May 23, 2013
Completion date
March 14, 2017
Enrollment
15 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer, peripheral arterial disease